Officially known as Approved Drug Products With Therapeutic Equivalence Evaluations, the FDA Orange Book contains a list of drugs considered by the FDA as both effective and safe. It does…
The post 3 Uses for Historical Versions of the FDA Orange Book …
3 Uses for Historical Versions of the FDA Orange Book Read Post »
SKLICE (ivermectin) Arbor pharms llc Patent: 6,103,248 Expiration: May 22, 2018 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected]…
The pos…
Drug Patent Expirations for the Week of May 20, 2018 Read Post »
Annual Drug Patent Expirations for CIALIS Cialis is a drug marketed by Lilly and is included in one NDA. It is available from eight suppliers. There are four patents protecting…
The post New patent expiration for LILLY drug CIALIS appeared first …
Annual Drug Patent Expirations for ADCIRCA Adcirca is a drug marketed by Eli Lilly Co and is included in one NDA. It is available from three suppliers. There are three…
The post New patent expiration for Eli Lilly drug ADCIRCA appeared first on D…
New patent expiration for Eli Lilly drug ADCIRCA Read Post »
Combination products offer companies new directions for drug patent innovation. Medicine has become more personalized over the past generation, and this has affected the drug patent system. One major trend…
The post Patents for Combination Produc…
Patents for Combination Products: Challenges and Opportunities Read Post »
Many readers have been asking for a simple way to get information on just a few drugs. While we do offer short-term three-month subscriptions, there is still a demand for…
The post Get single drug patent reports at DrugPatentWatch appeared first …
Get single drug patent reports at DrugPatentWatch Read Post »
This article was originally published by Andrew M Hill, Melissa J Barber, and Dzintars Gotham in BMJ Global Health Jan 2018, 3 (1) e000571 under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license. Abstract Introduction There are persi…
Estimated costs of production and potential prices for the WHO Essential Medicines List Read Post »
This article was originally published by Antti Jekunen in Drug Des Devel Ther. 2014; 8: 2009–2016 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract Decision-making is a core function…
The post Decision-makin…
By Larry Ramer, DrugPatentWatch writer A growing number of pharmaceutical companies are looking to simultaneously benefit from the low costs of developing generic treatments and the increased market share and…
The post Biobetters, Supergenerics H…
Biobetters, Supergenerics Hold Many Advantages for Pharma Companies Read Post »
This paper was originally published by Gail A.Van Norman, MD, in JACC: Basic to Translational Science Volume 1, Issue 5, August 2016, Pages 399-412 under a Creative Commons license. Summary The…
The post Drugs and Devices: Comparison of European …
Drugs and Devices: Comparison of European and U.S. Approval Processes Read Post »